Literature DB >> 17171534

Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation.

Lihua Zhang1, Wenbin Huang, Jieyu Chen, Xiaojun Zhou, Zhenfeng Lu, Hangbo Zhou.   

Abstract

The insulin-like growth factor (IGF) axis is a complex system composed of two mitogenic ligands, IGF-I and IGF-II, two receptors, IGF-IR and IGF-IIR, and six binding proteins, IGFBP1 to IGFBP6. The IGFBPs exert their actions through their regulation of IGF bioavailability for IGF receptors. The present study evaluated the correlation between IGFBP2 expression and clinicopathologic parameters and cell proliferation in cancer by using surgically resected tissue specimens from 97 patients with gastric carcinoma treated at our hospital. Immunohistochemical staining was performed using IGFBP2 and Ki-67 monoclonal antibody. An obvious difference existed in the IGFBP2 expression between carcinomas and normal mucosa. Correlation between IGFBP2 expression and the depth of penetration, lymph node metastasis, and clinical stage were observed. There was positive correlation between IGFBP2 expression and Ki-67 expression. We conclude that IGFBP2 may be involved in carcinogenesis and progression of gastric carcinoma by promoting cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171534     DOI: 10.1007/s10620-006-9358-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  27 in total

Review 1.  Novel aspects of the insulin-like growth factor binding proteins.

Authors:  L A Wetterau; M G Moore; K W Lee; M L Shim; P Cohen
Journal:  Mol Genet Metab       Date:  1999-10       Impact factor: 4.797

2.  Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum.

Authors:  J Pinto-De-Sousa; L David; M Seixas; A Pimenta
Journal:  Dig Surg       Date:  2001       Impact factor: 2.588

3.  Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors.

Authors:  N Boulle; A Logié; C Gicquel; L Perin; Y Le Bouc
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 4.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

Authors:  S Rajaram; D J Baylink; S Mohan
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

5.  Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium.

Authors:  Elin Richardsen; Tanja Ukkonen; Tone Bjørnsen; Elin Mortensen; Lars Egevad; Christer Busch
Journal:  Virchows Arch       Date:  2003-04-01       Impact factor: 4.064

6.  Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma.

Authors:  S U Han; J H Lee; W H Kim; Y K Cho; M W Kim
Journal:  World J Surg       Date:  1999-11       Impact factor: 3.352

7.  [IGFBP-2 mRNA expression in gastric cancer tissues and its roles in proliferation, differentiation and peritoneal metastasis of gastric cancer].

Authors:  Tao He; Xiao-ting Wu; Zhi-ming Yang; Ming-xu Da; Ming-ming Zhang; Kun Qian
Journal:  Sichuan Da Xue Xue Bao Yi Xue Ban       Date:  2005-03

8.  Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer.

Authors:  P C Konturek; S J Konturek; Z Sulekova; H Meixner; W Bielanski; T Starzynska; E Karczewska; K Marlicz; J Stachura; E G Hahn
Journal:  Aliment Pharmacol Ther       Date:  2001-07       Impact factor: 8.171

9.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

Authors:  L Bubendorf; M Kolmer; J Kononen; P Koivisto; S Mousses; Y Chen; E Mahlamäki; P Schraml; H Moch; N Willi; A G Elkahloun; T G Pretlow; T C Gasser; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

10.  Cyclooxygenase-2 expression and its relationship with proliferation of colorectal adenomas.

Authors:  Takanobu Sato; Keigo Yoshinaga; Satoshi Okabe; Takuya Okawa; Tetsuro Higuchi; Masayuki Enomoto; Touichirou Takizawa; Kenichi Sugihara
Journal:  Jpn J Clin Oncol       Date:  2003-12       Impact factor: 3.019

View more
  14 in total

1.  Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Authors:  Gianluca Marucci; Luca Morandi; Elisabetta Magrini; Anna Farnedi; Enrico Franceschi; Rossella Miglio; Daniela Calò; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2008-10-25       Impact factor: 4.064

Review 2.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09

3.  IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.

Authors:  Haibo Lu; Li Wang; Wen Gao; Jieru Meng; Bingbing Dai; Shuhong Wu; John Minna; Jack A Roth; Wayne L Hofstetter; Stephen G Swisher; Bingliang Fang
Journal:  Mol Cancer Ther       Date:  2013-10-15       Impact factor: 6.261

Review 4.  IGFBP2: integrative hub of developmental and oncogenic signaling network.

Authors:  Tao Li; M Elizabeth Forbes; Gregory N Fuller; Jiabo Li; Xuejun Yang; Wei Zhang
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

Review 5.  IGF-Binding Protein 2 - Oncogene or Tumor Suppressor?

Authors:  Adam Pickard; Dennis J McCance
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-27       Impact factor: 5.555

6.  FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma.

Authors:  Fubin Li; Yiping Li; Kewei Zhang; Ye Li; Ping He; Yujia Liu; Hongyan Yuan; Honghua Lu; Jinxiang Liu; Songtian Che; Zhenju Li; Li Bie
Journal:  Onco Targets Ther       Date:  2017-01-16       Impact factor: 4.147

7.  Long non-coding RNA HOTAIR promotes cell migration by upregulating insulin growth factor-binding protein 2 in renal cell carcinoma.

Authors:  Hiromichi Katayama; Keiichi Tamai; Rie Shibuya; Mao Nakamura; Mai Mochizuki; Kazunori Yamaguchi; Sadafumi Kawamura; Tatsuo Tochigi; Ikuro Sato; Takamasa Okanishi; Kunie Sakurai; Wataru Fujibuchi; Yoichi Arai; Kennichi Satoh
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

8.  Preoperative serum levels of insulin-like growth factor-binding protein 2 predict prognosis of gastric cancer patients.

Authors:  Hoon Hur; Eun Ji Yu; In-Hye Ham; Hye-Jin Jin; Dakeun Lee
Journal:  Oncotarget       Date:  2017-02-14

9.  Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with β-catenin in breast cancer lymph node metastasis.

Authors:  Priyanka Sehgal; Neeraj Kumar; Varuvar Rajesh Praveen Kumar; Shilpa Patil; Animesh Bhattacharya; Manavalan Vijaya Kumar; Geetashree Mukherjee; Paturu Kondaiah
Journal:  Mol Cancer       Date:  2013-06-16       Impact factor: 27.401

10.  Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival.

Authors:  Chengcheng Guo; Haibo Lu; Wen Gao; Li Wang; Kaihua Lu; Shuhong Wu; Apar Pataer; Maosheng Huang; Randa El-Zein; Tongyu Lin; Jack A Roth; Reza Mehran; Wayne Hofstetter; Stephen G Swisher; Xifeng Wu; Bingliang Fang
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.